Alphatec Spine, Inc. appears in FDA device records as the applicant behind a family of Calibrate interbody systems. The most recent record is K262646, a Traditional 510(k) received July 30, 2026 and decided October 21, 2026 with a substantially equivalent decision under product code MAX. The filing covers four named systems, and the FDA decision letter lists product codes MAX and MQP under 21 CFR 888.3080, Intervertebral Body Fusion Device, Class II. Earlier Calibrate filings in the same product code show a sequence of clearances for related configurations. [1][2][8]
The 2026 Calibrate MAX and CCX filing
K262646 names the Calibrate MAX System, Calibrate NanoTec MAX System, Calibrate CCX Interbody System and Calibrate NanoTec CCX Interbody System. The FDA record identifies the applicant as Alphatec Spine, Inc. at 1950 Camino Vida Roble, Carlsbad, California, with the submission received July 30, 2026 and a substantially equivalent decision dated October 21, 2026. The decision letter describes the review as covering nonclinical testing, including subsidence per ASTM F2267 and torsion testing per ASTM F2077, and concludes substantial equivalence to legally marketed devices on indications for use, intended use, design, technology and performance. [1][2]
Documented device construction
The manufacturer’s instructions for use describe the Calibrate NanoTec CCX Interbody System as an expandable lumbar intervertebral body fusion system intended for insertion through a posterior or transforaminal approach. Its spacers are made from titanium alloy (Ti-6Al-4V ELI) per ASTM F136 and PEEK Optima LT1 per ASTM F2026 with a nano-scale hydroxyapatite surface treatment, and the system includes spacers, inserters, trials and general instruments. The Calibrate CCX Interbody System instructions describe the same titanium and PEEK materials without the nano-scale hydroxyapatite treatment, and list parallel expansion and restoration of sagittal alignment among the system’s functions. [5][6][7]
Earlier Calibrate clearances
FDA records show prior clearances for related Calibrate configurations. K232504, decided October 13, 2023, covers the Calibrate CCX Interbody System under 21 CFR 888.3080, Class II, product code MAX, and states that the substantial equivalence determination was not based on an assessment of clinical performance data. K243461, decided March 4, 2025, covers the Calibrate Interbody Systems under the same regulation and product code, with a conclusion of substantial equivalence based on nonclinical testing. These records place the 2026 filing within a series of Calibrate submissions rather than an isolated event. [8][9]
What the record set shows and does not show
The linked collection contains one 510(k) record, K262646, with a decision count of one substantially equivalent decision; the single-record sample shows the same one decision. These figures describe the linked filings at the retrieval date and are not measures of total company sales, total portfolio or safety performance. The cited manufacturer instructions attribute the Alphatec Spine and ATEC Spine marks to Alphatec Holdings, Inc., its affiliates and/or subsidiary companies. That trademark notice does not by itself establish a specific corporate ownership structure. The Carlsbad address is an FDA filing address. [5][6][7] No recall records appear in the linked set. [1][2][8][9]



